Segment reporting (Tables)

12 Months Ended

Dec. 31, 2013

Summary of Segment Net Revenues, Segment Operating Income Loss and Reconciliation of Segment Income to Consolidated Income from Continuing Operations Before Income Taxes

The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:

	Year ended December 31,
	2013			2012			2011
Segment revenues:
U.S. dialysis and related lab services
Patient service revenues:
External sources	$	7,998,692		$	7,299,032		$	6,462,811
Intersegment revenues		34,080			17,786			11,141
Total dialysis and related lab services revenues		8,032,772			7,316,818			6,473,952
Less: Provision for uncollectible accounts		(281,146	)		(233,580	)		(190,234	)
Net dialysis and related lab services patient service revenues		7,751,626			7,083,238			6,283,718
Other revenues(1)		12,600			11,447			11,019
Total net dialysis and related lab services revenues		7,764,226			7,094,685			6,294,737
HCP
HCP revenues:
External sources	$	2,919,964		$	419,431		$	—
Intersegment revenues		250			—			—
Total HCP capitated revenues		2,920,214			419,431			—
Net patient service revenues		220,251			34,407			—
Other revenues		55,723			23,552			—
Total revenues	$	3,196,188		$	477,390		$	—
Other – Ancillary services and strategic initiatives
Net patient service revenues	$	75,852		$	16,824		$	7,730
Capitated revenues		67,351			61,906			45,133
Other external sources		694,763			553,261			395,347
Intersegment revenues		13,916			10,481			5,796
Total ancillary services and strategic initiatives revenues		851,882			642,472			454,006
Total net segment revenues		11,812,296			8,214,547			6,748,743
Elimination of intersegment revenues		(48,246	)		(28,267	)		(16,937	)
Consolidated net revenues	$	11,764,050		$	8,186,280		$	6,731,806
Segment operating margin (loss):(2)
U.S. dialysis and related lab services	$	1,211,540		$	1,378,241		$	1,235,869
HCP		385,253			66,930			—
Other—Ancillary services and strategic initiatives		(38,595	)		(64,877	)		(34,105	)
Total segment margin		1,558,198			1,380,294			1,201,764
Reconciliation of segment operating margin to consolidated income from continuing operations before income taxes:
Contingent earn-out obligation adjustment		56,977			—			—
Corporate support costs(3)		(65,041	)		(52,457	)		(47,051	)
Transaction expenses		—			(30,753	)		—
Consolidated operating income		1,550,134			1,297,084			1,154,713
Debt expense		(429,943	)		(288,554	)		(241,090	)
Debt refinancing and redemption charges		—			(10,963	)		—
Other income		4,787			3,737			2,982
Consolidated income from continuing operations before income taxes	$	1,124,978		$	1,001,304		$	916,605

(1) Includes management fees for providing management and administrative services to dialysis centers in which the Company owns a minority equity investment or which are wholly-owned by third parties.

(2) Certain costs previously reported in the ancillary services and strategic initiatives have been reclassified to U.S. dialysis and related lab services to conform to the current year presentation.

(3) Corporate support costs also include $7,721 of an adjustment to reduce a tax asset associated with the HCP acquisition escrow provisions.

Summary of Assets by Segment

Summary of assets by segment is as follows:

	December 31,
	2013		2012
Segment assets
U.S. dialysis and related lab services	$	10,248,993	$	9,351,466
HCP		6,265,767		6,228,403
Other—Ancillary services and strategic initiatives(1)		584,117		434,764
Consolidated assets	$	17,098,877	$	16,014,633

(1) Includes approximately $26 million and $13 million, respectively, of net property and equipment related to the Company’s international operations.